Innovative Compression System from L&R

    EWMA 2013: Rosidal® TCS produces impressive results in observational studies

    Very well tolerable, safe and comfortable: This is the result obtained in two current studies on the novel compression system Rosidal® TCS from Lohmann & Rauscher (L&R). The innovative two-component system was presented to the professional public at the European Wound Management Association (EWMA) conference held from 15-17 May in Copenhagen. With its extensive range of innovative products in the fields of debridement, wound care and compression, L&R also presented itself as a competent solution provider for its clients.

    With Rosidal® TCS, marketed in Great Britain as Actico2C, L&R enhances the therapy options for compression therapy of leg ulcers and their concomitant conditions. Now two current studies further emphasize the high clinical benefits of the innovative two-component system.

    Impressive study results for ulcers of varied origin

    The compression system proved its high usability once again in a multicentre, international post-marketing surveillance study (PMS) conducted on 102 leg ulcer patients.1 Rosidal® TCS (two-component system) showed very good results, particularly in patients with mixed and arterial leg ulcers, in relation to the general assessment, applicability, quality of life and potential for edema reduction.

    A second international multicentre study conducted on 95 leg ulcer patients confirmed the highly effective properties of Rosidal® TCS. In this indication, the compression system showed, even after one week’s application, an outstanding statistical stiffness index (SSI) of 16.5 (result directly after application: 18)2 and thus high stability of therapy.  

    Easy to apply and impressive wearing comfort

    The innovative padding compression bandage Rosidal® SC (Soft Compression) coupled with the latex-free cohesive short stretch compression bandage Rosidal® CC (Cohesive Compression) make up the two parts of the two-component system Rosidal® TCS. Rosidal® TCS combines both products in a safe system for the treatment of leg ulcers and their concomitant conditions. The soft padding compression bandage Rosidal® SC (Soft Compression) with integrated textile protection for sensitive skin supplies a therapeutically reliable pressure distribution while providing a high wearing comfort. The cohesive short stretch compression bandage Rosidal® CC (Cohesive Compression) adheres reliably to itself thus reducing the risk of slipping. The unique Safe-Loc System ensures that the required pressure is automatically achieved at full tension - easily, intuitively and safely. This ensures that the therapeutic working pressure is maintained over several days - and maintained with a simultaneously comfortably low resting pressure.

    The Rosidal® TCS system components are free of natural rubber latex making them a good alternative for people with latex hypersensitivity.

    Rosidal® TCS is distributed on the British market by the L&R company Activa Healthcare and is traded there under the name Actico2C as part of the successful Actico product range. When used in combination with gentle Debrisoft® for soft debridement, the moist wound care dressings of Suprasorb® and the superabsorbent dressing Vliwasorb® (traded by Activa Healthcare under the name Fliwasorb®) L&R offers a consistent overall approach for stage-appropriate wound care from the acute phase to the healing phase.

     

    You can find more on Rosidal® TCS and a video showing how to use the system at:
    www.lohmann-rauscher.com

    You can find more about Actico2C at:
    www.activahealthcare.co.uk

    References:

    1) S. Mazzei, G. Mosti, V. Dini, S. Bahr, A. Coulbourne, C. Hampel-Kalthofff, C. Zell, R. Brambilla, M. Abel. Umsetzung der Kompression in die Praxis - Ergebnisse einer Anwedungsstudie an dreizehn Ulcus cruris mixta oder arteriosum Patienten mit einem neuen Zwei-Komponenten System.

    2) S. Mazzei, G. Mosti, V. Dini, S. Bahr, A. Coulbourne, C. Hampel-Kalthofff, C. Zell, R. Brambilla, M. Abel. Ergebnisse einer Beobachtungsstudie an 95 Ulcus cruris Patienten mit einem neuen Zwei-Komponenten System (TCS).

     

    (3,708 characters incl. spaces and headings)

    Reprint free of charge / Voucher copy requested

    This website contains information on products and medical practices which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Medical practices and regulations can be different from one country to another.